• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, November 16, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Immune Checkpoint Inhibitor Toxicities Often Become Chronic, Study Finds

by
November 8, 2026
in Health
Reading Time: 5 mins read
0
Immune Checkpoint Inhibitor Toxicities Often Become Chronic, Study Finds

Immune Checkpoint Inhibitor Toxicities Often Become Chronic, Study Finds

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The research, published in Drugs – Real World Outcomes, analyzed data from 230 patients treated with ICIs between 2015 and 2024, providing a detailed characterization of the long-term sequelae and clinical workload associated with managing these toxicities. The findings indicate that approximately 61% of patients who developed irAEs experienced chronic complications, highlighting the enduring impact of these treatments on patient health and healthcare resource utilization.

The study aimed to investigate the likelihood of chronic irAEs, the challenges associated with their corticosteroid treatment, and the clinical workload required for their management. Immune checkpoint inhibitors are an established component of cancer therapy, capable of inducing long-lasting antitumor responses. However, over 50% of ICI-treated patients suffer from therapy-related toxicities, known as immune-related adverse events. The treatment of these events can be complex, requiring significant commitment from both the patient and the cancer care unit. The recurrence rate of irAEs is relatively high, and their clinical management is often complicated, necessitating a better understanding of their consequences to plan effective management strategies.

Researchers retrospectively collected data from patients whose cancer was treated with ICI therapy in the metastatic setting between January 1, 2015, and December 31, 2022, and in the adjuvant setting between January 1, 2015, and September 24, 2024. The majority of patients, 68.3%, were male, and the median age at the start of ICI therapy was 66.7 years. The most prevalent cancer types in the cohort were non-small cell lung cancer, accounting for 43.5% of cases, melanoma at 26.1%, and renal cell carcinoma at 13.0%. ICI monotherapy was administered to 76.5% of the patients, while 19.1% received ICI in combination with other treatments such as chemotherapy or tyrosine kinase inhibitors.

At least one irAE was observed in 60.4% of the patients in the study. For the analysis of irAE chronicity, 11 patients were excluded due to a follow-up time shorter than three months, leaving 128 patients in the irAE-positive cohort. Of these patients, 60.9% had at least one chronic adverse event. Chronic toxicities were defined as those that did not resolve within 12 weeks after the start of the event. The frequency of irAEs was found to be higher in adjuvant patients than in metastatic patients, with 82.1% of adjuvant patients experiencing irAEs compared to 57.4% of metastatic patients.

The most frequent chronic adverse events were thyroiditis, accounting for 39.4%, followed by hepatitis at 10.6%. Endocrine adverse events constituted 47.9% of all chronic AEs. In contrast, the most frequent acute adverse events were dermatitis and colitis. The study noted that certain irAEs were more likely to become chronic, including nervous system AEs, pancreatitis, and type 1 diabetes mellitus, all of which had a 100% rate of chronicity in the observed cases. Conversely, arthritis, pneumonitis, and colitis were least likely to become chronic, with colitis showing a 14.8% rate of chronicity.

The persistence of chronic irAEs was evaluated at the six-month time point and at the end of follow-up. Among patients who completed six months of follow-up, 50.9% still presented with at least one chronic adverse event. At the end of follow-up, this figure remained high at 50.8%. These findings suggest that once an irAE becomes chronic, it is unlikely to resolve spontaneously, indicating a long-term burden on patients. The median follow-up time for the cohort was 37.6 months, providing a substantial period to observe the durability of these toxicities.

Corticosteroid therapy remains the cornerstone of irAE management, particularly for severe or highly symptomatic cases. In this study, 42.9% of irAEs required systemic corticosteroid therapy. The duration of corticosteroid treatment was a significant factor in the development of steroid-related adverse events. In 49.3% of patients, corticosteroid therapy lasted for three months or longer. Longer corticosteroid usage was associated with an increased risk of steroid-related adverse events, with 78.8% of patients treated for three months or more experiencing such complications, compared to 38.2% of those treated for less than three months. The most common steroid-related adverse events included infections, swelling, new osteoporotic diagnoses or fractures, and new or worsening type 2 diabetes.

The clinical workload associated with managing irAEs was also quantified in the study. An average of 5.3 contacts with a medical oncologist was needed for the management of a single irAE. These contacts included outpatient visits, telephone calls, silent consultations, and hospitalizations. Phone calls constituted the majority of contacts, accounting for 60% of all interactions. The management of specific irAEs varied in workload; hepatitis was associated with the highest burden, requiring an average of 10.0 contacts per adverse event, followed by colitis with 6.1 contacts. In contrast, the management of thyroiditis and dermatitis required an average of 3.7 contacts each. This variation highlights the differing complexities and resource demands of different types of immune-related toxicities.

Hospital care for irAEs was required in 15.7% of all ICI-treated patients and 25.9% of those who developed an irAE. Hospitalization was equally common in acute and chronic irAEs, with no significant difference in rates between the two groups. The study found that hospitalization owing to irAEs significantly increased the overall inpatient time of ICI-treated patients, particularly in adjuvant settings. This finding underscores the impact of irAEs on healthcare resources and the need for efficient management strategies to minimize unnecessary hospital stays.

Consultations regarding the treatment of irAEs from medical oncology to other specialties were conducted via in-person visits, phone calls, hospital admissions, or silent consultations. The total number of consultations for irAEs was 158, corresponding to an average of 0.81 consultations per irAE. Phone consultations were the most frequent, constituting 83.5% of all consultations. Thyroiditis was the most common individual adverse event leading to consultation, with an average of 1.4 consultations per event, followed by hepatitis with 0.7 consultations. These data provide insight into the multidisciplinary nature of irAE management and the reliance on remote communication for coordinating care among different medical specialties.

The study acknowledges several limitations, including its retrospective, single-center design, which increased the risk of bias. The modest size of the cohort, especially the adjuvant group, restricted the statistical power of the findings and limited the possibility of performing detailed stratified analyses. Additionally, the inclusion of combinatorial therapies may have caused potential misclassification of adverse events, although the number of such cases was low. Despite these limitations, the study provides an accurate real-world description of ICI-treated patients and offers valuable insights into the long-term consequences of irAEs.

The characterization of the long-term sequelae of irAEs and the associated clinical workload is crucial for proper patient education and clinical resource planning. As the number of patients treated with ICIs increases annually, understanding the consequences of irAEs is important for assessing the effectiveness of ICI therapy. The findings suggest that robust risk factors for irAEs are lacking, making the characterization of long-term complications and the clinical workload generated by irAEs essential. Future prospective studies with longer follow-up and larger cohorts are required to assess patient quality of life and the risk-benefit profile of chronic irAEs more specifically.

Subject of Research: Long-term sequelae and clinical workload of immune checkpoint inhibitor toxicities

Article Title: The Long-Term Sequelae and Clinical Workload Resulting from Toxicities of Immune Checkpoint Inhibitor (ICI) Therapy in Patients with Cancer

Article References: Nurmela, V., Juntunen, A., Tiainen, S., Martikainen, J., Pasonen-Seppänen, S., & Rönkä, A. (2026). The Long-Term Sequelae and Clinical Workload Resulting from Toxicities of Immune Checkpoint Inhibitor (ICI) Therapy in Patients with Cancer. Drugs – Real World Outcomes, 13(3), 353-362. https://doi.org/10.1007/s40801-026-00561-x

Image Credits: AI Generated

DOI: 10.1007/s40801-026-00561-x

Keywords: immune checkpoint inhibitors, immune-related adverse events, cancer therapy, chronic toxicity, corticosteroids, clinical workload, retrospective study, oncology, Long-Term, Sequelae, Clinical, Workload

News Source: Nathaniel Bowman. (November 8, 2026). Immune Checkpoint Inhibitor Toxicities Often Become Chronic, Study Finds. Scienmag.

Tags: cancer therapychronic toxicityClinicalclinical workloadcorticosteroidsImmune checkpoint inhibitorsimmune-related adverse eventsLong-termOncologyRetrospective studySequelaeworkload
Share12Tweet7Share2ShareShareShare1

Related Posts

Mitochondrial Damage and Ferroptosis Interlock to Drive Bone Loss in Osteoporosis

Mitochondrial Damage and Ferroptosis Interlock to Drive Bone Loss in Osteoporosis

November 16, 2026
Posttraumatic Stress From Child-Related Trauma Predicts Poorer Perceived Health in Mothers

Posttraumatic Stress From Child-Related Trauma Predicts Poorer Perceived Health in Mothers

November 16, 2026

Italian RAADS-R Validation Identifies Candidate Cut-Offs in Adult Case-Control Study

November 16, 2026

Self-Help Mindful Intervention Reduces Parenting Stress in Multicenter Feasibility Trial

November 16, 2026

POPULAR NEWS

  • Information-Based Prescription Review Systems Evolve from Manual Screening to Intelligent Interception

    Information-Based Prescription Review Systems Evolve from Manual Screening to Intelligent Interception

    29 shares
    Share 12 Tweet 7
  • Study Reveals Incidence of Rare Pediatric Hip Disorders in Japanese Children

    29 shares
    Share 12 Tweet 7
  • Children With Nephrotic Syndrome Exhibit Severe Disruption Across Gut Microbial Kingdoms

    29 shares
    Share 12 Tweet 7
  • Automated Platform Maps Genomic Hotspots in CHO Cells for Antibody Production

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Freshwater Restoration Shows Higher Microbial Carbon Fixation in Yellow River Delta Wetlands

Clear-Cutting Loblolly Pine Shifts Ecosystem Carbon and Water Balance for Years

Mitochondrial Damage and Ferroptosis Interlock to Drive Bone Loss in Osteoporosis

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.